Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Citi Research

Trump tariffs could help clear the way for bigger tax cuts as Congress eyes a potential revenue windfall — and a shrinking economy

Economists at Citi Research said in a note on Thursday that the aggressive tariffs "may now become a justification for larger tax cuts."

Fortune

A rare Netflix skeptic on Wall Street says it fails the grandmother test: The winner of the streaming wars will have to do too much to stay on top

Citi's Jason Bazinet downgraded Netflix because of its narrative. "If you can explain a story in two lines to your grandmother, that will get a higher multiple"

Fortune

1,000 Reasons Why Starbucks Stock Fell Today

Starbucks workers are starting the longest strike in a yearlong unionization campaign. SBUX stock fell amid a weak overall market.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Here's How Citi Views Amylyx Pharma

Citi Research has raised the price target on Amylyx Pharmaceuticals Inc's (NASDAQ:AMLX) to $33 from $32, with a Buy rating. It says the small market opportunity for the newly approved amyotrophic lateral sclerosis (ALS) drug in Canada (~$100 million peak) bodes well for ongoing FDA review. Availability in Canada and using ALSFRS-R data as the primary basis…

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.